Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group-Reference-Cited by-同舟云学术

Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group

Published:2005-08 Issue:2 Volume:75 Page:124-129
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Papageorgiou Efstathios S.,Tsirigotis Panagiotis,Dimopoulos Meletios,Pavlidis Nikolaos,Fountzilas George,Papageorgiou Sotirios,Economopoulos Theofanis

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.2005.00482.x/fullpdf

Reference31 articles.

1. Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma

2. Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma

3. Gemcitabine as a Single Agent in the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

4. Treatment of refractory T-cell malignancies using gemcitabine

5. Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma;Journal of Comparative Effectiveness Research;2023-01

2. Cancers of the Blood;Fundamentals of Cancer Detection, Treatment, and Prevention;2022-05-13

3. Diffuse large B‐cell lymphoma: A consensus practice statement from the Australasian Lymphoma Alliance;Internal Medicine Journal;2021-09-16

4. Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy;Supportive Care in Cancer;2021-02-24

5. Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R‐Mini‐CYVE) regimen for patients with relapsed or refractory B‐cell non–Hodgkin’s lymphoma not eligible for intensive chemotherapy;European Journal of Haematology;2021-02-04